Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

BMS and Oncodesign enter into partnership: new drug candidates ahead!

Written by LVS on in the category news with the tags .


Today, Oncodesign announced a new strategic collaboration, the largest of the company to date. The French drug developer will provide its services to pharma titan Bristol-Myers Squibb in the search for novel small macrocycle drugs.

Using their Nanocyclix® technology platform, Oncodesign will identify and optimize novel compounds for targets of interest of Bristol-Myers Squibb. Macrocycles synthesized with Nanocyclix® technology are potent, selective and can be tweaked and modified to maximize effectiveness.

Oncodesign’s CSO Jan Hoflack is confident that its advanced pharmacology models will be of great use for their collaboration partner: “Nanocyclix has generated a broad diversity of entirely novel molecules that have unique properties and that seem to match well with the programs of interest to Bristol-Myers Squibb. We are honored that they have selected our technologies to advance on highly prioritized programs.”

In the course of 2015, Oncodesign grew with 170%, showing the best biotech performance on the French stock exchange. With the new Bristol-Myers Squibb collaboration, Oncodesign starts off the new year very auspicious.

Read more about Oncodesign and the Nanocyclix® technology platform in our interview with Jan Hoflack.

Read more about: .

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK Janssen Flanders.bio Turnstone KU Leuven Itera Life Science XpandInnovation V-Bio Ventures UGent Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.